Novo Nordisk faces $1.8 billion lawsuit over US insulin salesNovo Nordisk is facing a lawsuit from disgruntled investors seeking around $1.8 billion in compensation, saying the company Share XNovo Nordisk faces $1.8 billion lawsuit over US insulin saleshttps://pharmaphorum.com/news/novo-nordisk-faces-1-8-billion-lawsuit-over-us-insulin-sales/
Novo extends R&D alliance with AI specialist e-TherapeuticsNovo Nordisk must have liked what it saw in the first few months of its R&D tie-up with Share XNovo extends R&D alliance with AI specialist e-Therapeuticshttps://pharmaphorum.com/news/novo-extends-rd-alliance-with-ai-specialist-e-therapeutics/
Catalyst’s rival to NovoSeven hits the mark in phase 2 haemophilia trialCatalyst Biosciences is a step closer to challenging Novo Nordisk’s NovoSeven in the haemophilia A and B market Share XCatalyst’s rival to NovoSeven hits the mark in phase 2 haemophilia trialhttps://pharmaphorum.com/news/catalysts-rival-to-novoseven-hits-the-mark-in-phase-2-haemophilia-trial/
Novo Nordisk’s Victoza gets FDA okay for paediatric useNovo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the US as Share XNovo Nordisk’s Victoza gets FDA okay for paediatric usehttps://pharmaphorum.com/news/novo-nordisks-victoza-fda-paediatric-use/
Novo Nordisk builds cardio claim case for oral semaglutideNovo Nordisk’s bid to disrupt the diabetes market with an oral formulation of its GLP-1 agonist semaglutide has Share XNovo Nordisk builds cardio claim case for oral semaglutidehttps://pharmaphorum.com/news/novo-nordisk-builds-cardio-claim-case-for-oral-semaglutide/
Sanofi, Lilly and Novo make cases for diabetes drugs at ADAThe American Diabetes Association (ADA) annual conference has dominated the medical research headlines this weekend as pharma and Share XSanofi, Lilly and Novo make cases for diabetes drugs at ADAhttps://pharmaphorum.com/news/sanofi-lilly-and-novo-diabetes/
Beyond glucose in type 2 diabetes: how Novo Nordisk is looking to address chronic kidney diseaseAfter moving from academia to industry, Stephen Gough is now Novo Nordisk’s global chief medical officer, working on Share XBeyond glucose in type 2 diabetes: how Novo Nordisk is looking to address chronic kidney diseasehttps://pharmaphorum.com/r-d/views-analysis-r-d/beyond-glucose-in-type-2-diabetes-how-novo-nordisk-is-looking-to-address-chronic-kidney-disease/
Sanofi/Regeneron skin cancer drug among flurry of decisions from EU regulatorsA new drug for advanced skin cancer and a long-lasting treatment for haemophilia A are among a group Share XSanofi/Regeneron skin cancer drug among flurry of decisions from EU regulatorshttps://pharmaphorum.com/news/sanofi-regeneron-skin-cancer-drug-among-flurry-of-approvals-from-eu-regulators/
FDA approves PureTech’s obesity device PlenityThe FDA has approved PureTech Health’s ‘space occupying’ device Plenity as a new prescription treatment for obesity, setting Share XFDA approves PureTech’s obesity device Plenityhttps://pharmaphorum.com/news/fda-approves-puretech-obesity-plenity/
